SEARCH

SEARCH BY CITATION

References

  • AKARASEREENONT, P., MITCHELL, J.A., APPLETON, I., THIEMERMANN, C. & VANE, J.R. (1994). Involvement of tyrosine kinase in the induction of cyclo-oxygenase and nitric oxide synthase by endotoxin in cultured cells. Br. J. Pharmacol., 113, 15221528.
  • BARTLETT, R.R., ANAGNOSTOPULOS, H., ZIELINSKI, T., MATTAR, T. & SCHLEYERBACH, R. (1993). Effects of leflunomide on immune responses and models of inflammation. Springer Semin. Immunopathol., 14, 381394.
  • BARTLETT, R.R., DIMITRIJEVIC, M., MATTAR, AT., ZIELINSKI, T., GERMANN, T., RUDE, E., THOENES, G.H., KUCHLE, C.C., SCHORLEMMER H.U. & BREMER, E. (1991). Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplant rejection. Agents Actions, 32, 1021.
  • CURNOCK, A.P., ROBSON, P.A., YEA, C.M., MOSS, D., GADHER, S., THOMSON, T.A., WESTWOOD, R., RUUTH, E. & WILLIAMSON, R.A. (1997). Potencies of leflunomide and HR325 as inhibitors of prostaglandin endoperoxide H synthase-1 and -2: comparison with nonsteroidal anti-inflammatory drugs. J. Pharmacol. Exp. Ther., 282, 339347.
  • GIERSE, J.K., KOBOLDT, C.M., WALKER, M.C., SEIBERT, K. & ISAKSON, P.C. (1999). Kinetic basis for selective inhibition of cyclooxygenases. Biochem. J., in press.
  • HAMILTON, L.C. & WARNER, T.D. (1998). Interactions between inducible isoforms of nitric oxide synthase and cyclo-oxygenase in vivo: investigations using the selective inhibitors 1400W and celecoxib. Br. J. Pharmacol., 125, 330340.
  • HAMILTON, L.C., MITCHELL, J.A., TOMLINSON, A. & WARNER, T.D. (1999). Synergy between cyclooxygenase-2 induction and arachidonic acid supply in vivo: consequences for nonsteroidal anti-inflammatory drug efficacy. FASEB J., 13, 245251.
  • HAMILTON, L.C., VOJNOVIC, I., BAKHLE, Y.S., WARNER, T.D. & VANE, J.R. (1997). The anti-inflammatory drug leflunomide inhibits in vitro and in vivo the activity of COX-2 more potently than the induction of COX-2 or iNOS. Br. J. Pharmacol., 120, 49.
  • HLA, T., RISTIMAKI, A., APPLEBY, S. & BARRIOCANAL, J.G. (1993). Cyclooxygenase gene expression in inflammation and angiogenesis. Ann. N.Y. Acad. Sci., 696, 197204.
  • LANEUVILLE, O., BREUER, D.K., DEWITT, D.L., HLA, T., FUNK, C.D. & SMITH, W.L. (1994). Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J. Pharmacol. Exp. Ther., 271, 927934.
  • LORSBACH, R.B., MURPHY, W.J., LOWENSTEIN, C.J., SNYDER, S.H. & RUSSELL, S.W. (1993). Expression of the nitric oxide synthase gene in mouse macrophages activated for tumor cell killing. Molecular basis for the synergy between interferon-gamma and lipopolysaccharide. J. Biol. Chem., 268, 19081913.
  • MARCZIN, N., PAPAPETROPOULOS, A. & CATRAVAS, J.D. (1993). Tyrosine kinase inhibitors suppress endotoxin and IL-1 beta induced NO synthesis in aortic smooth muscle cells. Am. J. Physiol., 265, H1014H1018.
  • MATTAR, T., KOCHHAR, K., BARTLETT, R., BREMER, E.G. & FINNEGAN, A. (1993). Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett., 334, 161164.
  • MITCHELL, J.A., AKARASEREENONT, P., THIEMERMANN, C., FLOWER, R.J. & VANE, J.R. (1993). Selectivity of nonsteroid anti-inflammatory drugs as inhibitors of constitutive and inducible cyclo-oxygenase. Proc. Natl. Acad. Sci. U.S.A., 90, 1169311697.
  • MITCHELL, J.A., BELVISI, M.G., AKARASEREENONT, P., ROBBINS, R.A., KWON, O.J., CROXTALL, J., BARNES, P.J. & VANE, J.R. (1994). Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. Br. J. Pharmacol., 113, 10081014.
  • MITCHELL, J.A., SAUNDERS, M., BARNES, P.J., NEWTON, R. & BELVISI, M.G. (1997). Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor kappaB) activation: role of arachidonic acid. Mol. Pharmacol., 51, 907912.
  • MLADENOVIC, V., DOMLJAN, Z., ROZMAN, B., JAJIC, I., MITHAJLOVIC, D., DORDEVIC, J., POPOVIC, M., DIMITRIJEVIC, M., ZIKOVIC, M., CAMPION, G., MUSIKIC, P., LOWFRIEDRICH, I., OED, C., SEIFERT, H. & STRAND, V. (1995). Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum., 38, 15951603.
  • SAUNDERS, M.A., BELVISI, M.G., CORDEN, M.B., FOX, A.J., EVANS, T.W., BARNES, P.J. & MITCHELL, J.A. (1996). Exacerbation of the release of prostaglandin (PG) E2 by bradykinin after COX-2 induction in human airway epithelial cells. Br. J. Pharmacol., 119, P46.
  • SEIBERT, K. & MASFERRER, J.L. (1994). Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor, 4, 1723.
  • SILVA, J.H. & MORRIS, R.E. (1997). Leflunomide and malononitrilamides. Am. J. Med. Sci., 313, 289301.
  • SMOLEN, J.S., KALDEN, J.R., SCOTT, D.L., ROZMAN, B., KVIEN, T.K., LARSEN, A., LOEW-FRIEDRICH, I., OLD, C. & ROSENBURG, R. (1999). Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet, 353, 259266.
  • STEUR, D.J. & MARLETTA, M.A. (1989). Induction of nitrite/nitrate synthesis in murine macrophages by BCG infection, lymphokines or interferon-gamma. J. Immunol., 139, 518525.
  • SWIERKOSZ, T.A., MITCHELL, J.A., WARNER, T.D., BOTTING, R.M. & VANE, J.R. (1995). Co-induction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids. Br. J. Pharmacol., 114, 13351342.
  • SZABO, C., SOUTHAN, G.J. & THIEMERMANN, C. (1994). Beneficial effects and improved survival in rodent models of septic shock with S-methylisothiourea sulfate, a potent and selective inhibitor of inducible nitric oxide synthase. Proc. Natl. Acad. Sci. U.S.A., 91, 1247212476.
  • THIEMERMANN, C. (1993). Drugs which modulate nitric oxide homeostasis are likely to provide therapeutic benefit in cardiovascular disease. Cardiovasc. Res., 27, 2104.
  • TOMLINSON, A., APPLETON, I., MOORE, A.R., GILROY, D.W., WILLIS, D., MITCHELL, J.A. & WILLOUGHBY, D.A. (1994). Cyclo-oxygenase and nitric oxide synthase isoforms in rat carrageenin-induced pleurisy. Br. J. Pharmacol., 113, 693698.
  • VANE, J.R. (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol., 231, 232235.
  • VANE, J.R., MITCHELL, J.A., APPLETON, I., TOMLINSON, A., BISHOP-BAILEY, D., CROXTALL, J. & WILLOUGHBY, D.A. (1994). Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc. Natl. Acad. Sci. U.S.A., 91, 20462050.
  • XIE, Q.W., CHO, H.J., CALAYCAY, J., MUMFORD, R.A., SWIDEREK, K.M., LEE, T.D., DING, A., TROSO, T. & NATHAN, C. (1992). Cloning and characterisation of inducible nitric oxide synthase from murine macrophages. Science, 256, 225228.
  • XIE, W.L., CHIPMAN, J.G., ROBERTSON, R.L., ERIKSON, R.L. & SIMMONS, D.L. (1991). Expression of a mitogen responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Acad. Sci. U.S.A., 88, 26922696.